Recombinant
RabMAb

Recombinant Anti-FGF2 antibody [EPR20145-227] (ab215373)

Submit a review Submit a question

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EPR20145-227] to FGF2
  • Suitable for: WB, IP
  • Reacts with: Human

Overview

  • Product name

    Anti-FGF2 antibody [EPR20145-227]
    See all FGF2 primary antibodies

  • Description

    Rabbit monoclonal [EPR20145-227] to FGF2

  • Host species

    Rabbit

  • Tested applications

    Suitable for: WB, IPmore details

  • Species reactivity

    Reacts with: Human

  • Immunogen

    Recombinant full length protein within Human FGF2 aa 100 to the C-terminus. The exact sequence is proprietary. Mature protein minus the propeptide.
    Database link: P09038

  • Positive control

    • WB: Recombinant human FGF2 active protein (aa143-288); K562, U-87 MG and SK-OV-3 whole cell lysates; Human fetal heart, fetal brain and fetal kidney lysates. IP: K562 whole cell lysate.

  • General notes

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

Properties

Applications

Our Abpromise guarantee covers the use of ab215373 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000. Detects a band of approximately 34, 24, 22, 18 kDa (predicted molecular weight: 30 kDa).
IP 1/30.

Target

  • Function

    Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. Functions as potent mitogen in vitro. Can induce angiogenesis (PubMed:23469107).

  • Tissue specificity

    Expressed in granulosa and cumulus cells. Expressed in hepatocellular carcinoma cells, but not in non-cancerous liver tissue.

  • Sequence similarities

    Belongs to the heparin-binding growth factors family.

  • Post-translational
    modifications

    Phosphorylation at Tyr-215 regulates FGF2 unconventional secretion.
    Several N-termini starting at positions 94, 125, 126, 132, 143 and 162 have been identified by direct sequencing.

  • Cellular localization

    Secreted. Nucleus. Exported from cells by an endoplasmic reticulum (ER)/Golgi-independent mechanism. Unconventional secretion of FGF2 occurs by direct translocation across the plasma membrane. Binding of exogenous FGF2 to FGFR facilitates endocytosis followed by translocation of FGF2 across endosomal membrane into the cytosol. Nuclear import from the cytosol requires the classical nuclear import machinery, involving proteins KPNA1 and KPNB1, as well as CEP57.
  • Information by UniProt

  • Database links

    • Alternative names

      • Basic fibroblast growth factor antibody
      • Basic fibroblast growth factor bFGF antibody
      • BFGF antibody
      • FGF 2 antibody
      • FGF B antibody
      • FGF-2 antibody
      • Fgf2 antibody
      • FGF2 basic antibody
      • FGF2_HUMAN antibody
      • FGFB antibody
      • Fibroblast growth factor 2 (basic) antibody
      • Fibroblast growth factor 2 antibody
      • Fibroblast growth factor, basic antibody
      • HBGF 2 antibody
      • HBGF-2 antibody
      • HBGF2 antibody
      • HBGH 2 antibody
      • HBGH2 antibody
      • Heparin binding growth factor 2 precursor antibody
      • Heparin-binding growth factor 2 antibody
      • Prostatropin antibody
      see all

    Images

    • Western blot - Anti-FGF2 antibody [EPR20145-227] (ab215373)
      Western blot - Anti-FGF2 antibody [EPR20145-227] (ab215373)
      All lanes : Anti-FGF2 antibody [EPR20145-227] (ab215373) at 1/1000 dilution

      Lane 1 : K562 (Human chronic myelogenous leukemia cell line from bone marrow) whole cell lysate
      Lane 2 : U-87 MG (Human glioblastoma-astrocytoma epithelial cell line) whole cell lysate
      Lane 3 : SK-OV-3 (Human ovarian cancer cell line) whole cell lysate

      Lysates/proteins at 10 µg per lane.

      Secondary
      All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution

      Predicted band size: 30 kDa
      Observed band size: 18,22,24,34 kDa
      why is the actual band size different from the predicted?



      Blocking/Dilution buffer: 5% NFDM/TBST.

      Exposure time: Lane 1/2: 3 minutes; Lane 3: 1 minute.

      The MW observed is consistent with the literatures (PMID:18850066, PMID: 24827991).

    • Western blot - Anti-FGF2 antibody [EPR20145-227] (ab215373)
      Western blot - Anti-FGF2 antibody [EPR20145-227] (ab215373)
      Anti-FGF2 antibody [EPR20145-227] (ab215373) at 1/10000 dilution + Recombinant human FGF2 active protein (aa143-288) at 0.01 µg

      Secondary
      Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution

      Predicted band size: 30 kDa
      Observed band size: 17 kDa why is the actual band size different from the predicted?


      Exposure time: 3 seconds


      Blocking/Dilution buffer: 5% NFDM/TBST.

    • Western blot - Anti-FGF2 antibody [EPR20145-227] (ab215373)
      Western blot - Anti-FGF2 antibody [EPR20145-227] (ab215373)
      All lanes : Anti-FGF2 antibody [EPR20145-227] (ab215373) at 1/1000 dilution

      Lane 1 : Human fetal heart lysate
      Lane 2 : Human fetal brain lysate
      Lane 3 : Human fetal kidney lysate

      Lysates/proteins at 10 µg per lane.

      Secondary
      All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution

      Predicted band size: 30 kDa
      Observed band size: 24,34 kDa why is the actual band size different from the predicted?



      Blocking/Dilution buffer: 5% NFDM/TBST.

      Exposure time: Lane 1/2: 3 minutes; Lane 3: 1 minute.

      The MW observed is consistent with the literatures (PMID:18850066, PMID: 24827991).

    • Immunoprecipitation - Anti-FGF2 antibody [EPR20145-227] (ab215373)
      Immunoprecipitation - Anti-FGF2 antibody [EPR20145-227] (ab215373)

      FGF2 was immunoprecipitated from 0.35 mg of K562 (Human chronic myelogenous leukemia cell line from bone marrow) whole cell lysate with ab215373 at 1/30 dilution.

      Western blot was performed from the immunoprecipitate using ab215373 at 1/500 dilution.

      VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/1,000 dilution

      Lane 1: K562 whole cell lysate 10µg (Input).

      Lane 2: ab215373 IP in K562 whole cell lysate.

      Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab215373 in K562 whole cell lysate.

      Blocking and dilution buffer and concentration: 5% NFDM/TBST.

      Exposure time: 1 second.

    References

    Publishing research using ab215373? Please let us know so that we can cite the reference in this datasheet.

    ab215373 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    Show All Reviews Q&A
    Submit a review Submit a question

    There are currently no Customer reviews or Questions for ab215373.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com